Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

1362602

USP

Levonorgestrel

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H28O2
Numero CAS:
797-63-7
Peso molecolare:
312.45
Numero MDL:
MFCD00199013
Codice UNSPSC:
41116107
ID PubChem:
329750050
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

levonorgestrel

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
WWYNJERNGUHSAO-XUDSTZEESA-N

Informazioni sul gene

human ... PGR(5241)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H351,H360D,H362

Classi di pericolo

Carc. 2 - Lact. - Repr. 1A

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

Norethindrone United States Pharmacopeia (USP) Reference Standard

USP

1469005

Norethindrone

Ethinylestradiol European Pharmacopoeia (EP) Reference Standard

E1900000

Ethinylestradiol

Sigma-Aldrich

Sigma-Aldrich

89904

Micro particles based on polystyrene

17α-Ethynylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethynylestradiol

Ian S Fraser
Contraception, 87(3), 273-279 (2012-10-09)
It has been recognized for well over half a century that hormonal preparations designed as contraceptives are also capable of offering health benefits through the treatment and prevention of benign gynecological disease and even some systemic conditions. Increasing attention is
Ahmed M Abou-Setta et al.
The Cochrane database of systematic reviews, 1(1), CD005072-CD005072 (2013-02-27)
Various options exist for treating endometriosis, including surgical, medical, such as ovarian suppression, or a combination of these strategies. Surgical treatment of endometriosis aims to remove visible areas of endometriosis. The aim of medical therapy is to inhibit growth of
T E Roberts et al.
BMJ (Clinical research ed.), 342, d2202-d2202 (2011-04-28)
To undertake a cost effectiveness analysis comparing first and second generation endometrial ablative techniques, hysterectomy, and the levonorgestrel releasing intrauterine system (Mirena) for treating heavy menstrual bleeding. Model based economic evaluation with data from an individual patient data meta-analysis supplemented
H K Kroupova et al.
Aquatic toxicology (Amsterdam, Netherlands), 154, 154-162 (2014-06-04)
The aim of the present study was to investigate the effects of the synthetic progestin levonorgestrel (LNG) on the reproductive endocrine system of a teleost fish, the roach (Rutilus rutilus). Pubertal roach were exposed for 28 days in a flow-through
Andrew M Kaunitz et al.
Drugs, 72(2), 193-215 (2012-01-25)
Heavy menstrual bleeding (HMB) is a common problem in women of reproductive age and can cause irritation, inconvenience, self-consciousness and fear of social embarrassment. Our objective was to review and appraise literature identified from the MEDLINE and EMBASE databases to
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.